Dr. Choi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3855 Health Sciences Dr
La Jolla, CA 92093Phone+1 858-822-0863Fax+1 858-246-1847- Is this information wrong?
Education & Training
- University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2005 - 2008
- Keck School of Medicine of the University of Southern CaliforniaClass of 2005
Certifications & Licensure
- CA State Medical License 2007 - 2024
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Young Investigator Award Tower Cancer Research Foundation, 2012
Clinical Trials
- UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2014 Aug 08
- Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL Start of enrollment: 2016 Jun 01
- Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome Start of enrollment: 2017 Dec 20
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsMetastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells.Botta, G., Chao, J., Ma, H., Hahn, M., Sierra, G., Jia, J., Hendrix, A., Nolte Fong, J., Ween, A., Vu, P., Miller, A., Choi, M., Heyman, B., Daniels, G., Kaufman, D., ...> ;Journal for Immunotherapy of Cancer. 2024 Feb 5
- Novel BRAF N581S mutation in mantle cell lymphoma.Heyman, B., Hariharan, N., Bedi, D., Choi, M., Wang, H.> ;Ejhaem. 2024 Feb 1
- A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation.Benjamin Heyman, Michael Choi, Thomas J Kipps> ;Case Reports in Hematology. 2024 Jan 1
- Join now to see all
Abstracts/Posters
- Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Michael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular TherapiesMichael Y. Choi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
- Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual MeetingDecember 9th, 2019
- Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with IbrutinibJune 3rd, 2019
- Oncternal Therapeutics to Present Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib at the 2019 American Society of Clinical Oncology Annual MeetingMay 15th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: